To study the response rate and toxic side effects of vindesine, aclarubicin and mitomycin(VAM) as a new regimen of second line chemotherapy for ovarian carcinoma.
目的研究长春酰胺、阿克拉霉素、丝裂霉素联合化疗治疗耐药卵巢癌的疗效和毒性反应。
To study the response rate and toxic side effects of vindesine, aclarubicin and mitomycin(VAM) as a new regimen of second line chemotherapy for ovarian carcinoma.
目的研究长春酰胺、阿克拉霉素、丝裂霉素联合化疗治疗耐药卵巢癌的疗效和毒性反应。
应用推荐